Literature DB >> 18549978

Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?

Elizabeth R Rayburn1, Ruiwen Zhang.   

Abstract

Antisense oligonucleotides can regulate gene expression in living cells. As such, they regulate cell function and division, and can modulate cellular responses to internal and external stresses and stimuli. Although encouraging results from preclinical and clinical studies have been obtained and significant progress has been made in developing these agents as drugs, they are not yet recognized as effective therapeutics. Several major hurdles remain to be overcome, including problems with efficacy, off-target effects, delivery and side effects. The lessons learned from antisense drug development can help in the development of other oligonucleotide-based therapeutics such as CpG oligonucleotides, RNAi and miRNA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18549978      PMCID: PMC2497463          DOI: 10.1016/j.drudis.2008.03.014

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  76 in total

1.  Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells.

Authors:  Makoto Miyagishi; Mariko Hayashi; Kazunari Taira
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2003-02

Review 2.  The Bcl-2 apoptotic switch in cancer development and therapy.

Authors:  J M Adams; S Cory
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

3.  RNA silencing: genomic defence with a slice of pi.

Authors:  Phillip D Zamore
Journal:  Nature       Date:  2007-04-19       Impact factor: 49.962

Review 4.  SELEX experiments: new prospects, applications and data analysis in inferring regulatory pathways.

Authors:  Marko Djordjevic
Journal:  Biomol Eng       Date:  2007-03-12

Review 5.  Therapeutic potential for microRNAs.

Authors:  Christine C Esau; Brett P Monia
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

Review 6.  Polymorphic miRNA-mediated gene regulation: contribution to phenotypic variation and disease.

Authors:  Michel Georges; Wouter Coppieters; Carole Charlier
Journal:  Curr Opin Genet Dev       Date:  2007-04-30       Impact factor: 5.578

7.  Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

Authors:  Susan O'Brien; Joseph O Moore; Thomas E Boyd; Loree M Larratt; Aleksander Skotnicki; Benjamin Koziner; Asher A Chanan-Khan; John F Seymour; R Gregory Bociek; Steve Pavletic; Kanti R Rai
Journal:  J Clin Oncol       Date:  2007-02-12       Impact factor: 44.544

8.  Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients.

Authors:  Hui Wang; Mao Li; Wenyao Lin; Wenquan Wang; Zhuo Zhang; Elizabeth R Rayburn; Jian Lu; Deng Chen; Xinsen Yue; Fuming Shen; Feng Jiang; Jie He; Wu Wei; Xiaofei Zeng; Ruiwen Zhang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-04       Impact factor: 4.254

Review 9.  Targeting different signaling pathways with antisense oligonucleotides combination for cancer therapy.

Authors:  C Leonetti; G Zupi
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

View more
  50 in total

1.  Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation.

Authors:  Dan Zheng; David A Giljohann; David L Chen; Matthew D Massich; Xiao-Qi Wang; Hristo Iordanov; Chad A Mirkin; Amy S Paller
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-06       Impact factor: 11.205

Review 2.  Insights on chiral, backbone modified peptide nucleic acids: Properties and biological activity.

Authors:  Maria Moccia; Mauro F A Adamo; Michele Saviano
Journal:  Artif DNA PNA XNA       Date:  2016-01-11

3.  Tailoring of chronic lymphatic leukemia therapy.

Authors:  Ashraf M Elhefni
Journal:  Am J Blood Res       Date:  2013-08-19

4.  Hydrolysis of bulged nucleotides in hybrids formed by RNA and imidazole-derivatized oligo-2'-O-methylribonucleotides.

Authors:  Anthony D Saleh; Paul S Miller
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2011-03       Impact factor: 1.381

5.  Microfluidic assembly of lipid-based oligonucleotide nanoparticles.

Authors:  Bo Yu; Jing Zhu; Weiming Xue; Yun Wu; Xiaomeng Huang; L James Lee; Robert J Lee
Journal:  Anticancer Res       Date:  2011-03       Impact factor: 2.480

Review 6.  MicroRNAs and cardiac pathology.

Authors:  Michael V G Latronico; Gianluigi Condorelli
Journal:  Nat Rev Cardiol       Date:  2009-06       Impact factor: 32.419

Review 7.  Nucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges.

Authors:  Michael Zakrewsky; Sunny Kumar; Samir Mitragotri
Journal:  J Control Release       Date:  2015-09-15       Impact factor: 9.776

8.  Topical delivery of siRNA into skin using SPACE-peptide carriers.

Authors:  Ming Chen; Michael Zakrewsky; Vivek Gupta; Aaron C Anselmo; Deborah H Slee; John A Muraski; Samir Mitragotri
Journal:  J Control Release       Date:  2014-01-13       Impact factor: 9.776

9.  Antisense oligonucleotide mediated knockdown of HOXC13 affects cell growth and induces apoptosis in tumor cells and over expression of HOXC13 induces 3D-colony formation.

Authors:  Sahba Kasiri; Khairul I Ansari; Imran Hussain; Arunoday Bhan; Subhrangsu S Mandal
Journal:  RSC Adv       Date:  2012-12-18       Impact factor: 3.361

10.  Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis.

Authors:  Qing-He Nie; Chuan-Long Zhu; Ya-Fei Zhang; Jie Yang; Jiu-Cong Zhang; Ren-Tao Gao
Journal:  Dig Dis Sci       Date:  2009-06-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.